Back

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

25 August 2023 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Remodelling, prognosis, and outcomes in atrial fibrillation Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Doralisa Morrone

Cisanello Hospital, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
Duration of left and right atrial activation wavefront assessed non-invasively is significantly higher in patients with atrial fibrillation than in controls.
Doctor L. Parreira (Setubal, PT)
Abstract Slides Video
Presentation thumbnail
The risk and cause of death according to prevalent atrial fibrillation and the role of CHA2DS2-VASc score to stratify the risk of all-cause and cardiovascular death
Doctor Y. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Lower risk of atrial fibrillation development associated with SGLT-2 inhibitors in type 2 diabetic patients compared to DPP-4 inhibitors: a nationwide cohort study
Doctor J. Lee (Cheongju, KR)
Abstract Slides
Presentation thumbnail
Impact of atrial fibrillation burden on longitudinal changes in left ventricular structure and function: a post-hoc analysis of a randomized clinical trial
Miss F. Vyff (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Prognostic significance of thyroid disease in atrial fibrillation
Doctor A. Papazoglou (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Remodelling, prognosis, and outcomes in atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Session
Registries on atrial fibrillation and sudden death
thumbnail
Congress Presentation
Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
thumbnail
Congress Presentation
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources